Leukaemia & Lymphoma Research has appointed Pelham Allen as its new Chair, as the charity steps up its work to beat blood cancer. The appointment comes as Leukaemia & Lymphoma Research completes a record year for investment in research (£32.5m in 2012/13, their highest ever).
Pelham brings a wealth of experience to the role, having held senior positions in the corporate, public and not-for-profit sectors – this experience will be crucial as Leukaemia & Lymphoma Research aims to expand not only its research, but its patient support, information, policy and influencing functions.
As the current Chair of London Cancer, and formerly an advisor to a number of NHS trusts, Pelham’s experience will be of huge benefit to the charity as research and patient services come to terms with the new NHS structure. In addition, having been a Hodgkin lymphoma patient, he is ideally placed to understand the personal needs of patients.
Retiring Chair Richard Delderfield welcomed the appointment, saying:
“At this exciting time for Leukaemia & Lymphoma Research, the skills and knowledge Pelham brings with him will be invaluable in accelerating our progress. He has experience of working in business, the charity sector and the NHS, all of which will be crucial to helping us beat blood cancer.”
On his appointment, Pelham Allen said:
“I am delighted to be joining Leukaemia & Lymphoma Research at such a significant point in their history. After a record year of investment in research, there are some ambitious and exciting plans for the future, which I look forward to helping deliver.”
Pelham will attend the Board meeting in November, and then assume the position from there.